Account
Inquiry
QSC Tirzepatide is a novel dual GIP and GLP-1 receptor agonist that has shown significant potential in metabolic research. This synthetic peptide demonstrates superior pharmacological effects compared to single GLP-1 receptor agonists, making it valuable for scientific investigations into diabetes and obesity-related conditions.
The molecular mechanism of QSC Tirzepatide involves simultaneous activation of both GIP and GLP-1 receptors, which contributes to its enhanced glucose-dependent insulin secretion and appetite suppression effects. Research indicates this dual agonism may offer superior metabolic benefits compared to single-receptor targeting compounds.
For laboratory use, QSC Tirzepatide is supplied as a white lyophilized powder with high stability when stored properly. The compound has demonstrated dose-dependent effects in preclinical models, with particular interest in its potential applications for metabolic syndrome research.
Key research applications include: investigation of insulin secretion mechanisms, studies of appetite regulation, metabolic syndrome research, and exploration of novel diabetes treatment approaches. The compound's unique dual-receptor activity profile makes it particularly valuable for comparative pharmacological studies.
